CN1231255C - Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method - Google Patents
Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method Download PDFInfo
- Publication number
- CN1231255C CN1231255C CN 200410013663 CN200410013663A CN1231255C CN 1231255 C CN1231255 C CN 1231255C CN 200410013663 CN200410013663 CN 200410013663 CN 200410013663 A CN200410013663 A CN 200410013663A CN 1231255 C CN1231255 C CN 1231255C
- Authority
- CN
- China
- Prior art keywords
- cucurbitae moschatae
- fructus cucurbitae
- raw material
- capsule
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000002994 raw material Substances 0.000 title claims abstract description 26
- 235000000832 Ayote Nutrition 0.000 title abstract 5
- 235000009854 Cucurbita moschata Nutrition 0.000 title abstract 5
- 240000001980 Cucurbita pepo Species 0.000 title abstract 5
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 title abstract 5
- 235000015136 pumpkin Nutrition 0.000 title abstract 5
- 239000007963 capsule composition Substances 0.000 title description 3
- 206010010774 Constipation Diseases 0.000 claims abstract description 48
- 239000002775 capsule Substances 0.000 claims abstract description 22
- 241001116389 Aloe Species 0.000 claims abstract description 16
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 16
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 12
- 241001506047 Tremella Species 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- 238000000227 grinding Methods 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 20
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000013872 defecation Effects 0.000 abstract description 35
- 230000000694 effects Effects 0.000 abstract description 16
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 6
- 206010012735 Diarrhoea Diseases 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000012535 impurity Substances 0.000 abstract description 2
- 239000008141 laxative Substances 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000001543 purgative effect Effects 0.000 abstract description 2
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000002040 relaxant effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 244000269722 Thea sinensis Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000013580 sausages Nutrition 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a formula of a capsule prepared from pumpkin as a main raw material for treating constipation and a preparation method of the capsule. The ubiquitous problems of traditionally cathartic products are mainly solved that drastic purgative components as main bodies can cause stomachache, diarrhea, humoral imbalance, enteric plexus nerve damage, etc. after taken, and dependence phenomena can occur easily; in addition, materials processed by a traditional technology have the disadvantages of insufficient grain fineness, low biological availability and unfavorable clinic effect. The present invention has the technical scheme that the capsule is made from 7 raw materials of pumpkin peel, pumpkin stalk, pumpkin collateral, Poria, tremella, xylo oligosaccharide and aloe. The preparation method comprises the following steps: impurity removing, extracting, decocting, low temperature drying and superfine grinding processing. The capsule of the present invention is suitable for treating intractable constipation caused by various reasons for old and frail persons, puerpera, children, postoperative patients, etc., and has the advantages of low dosage, rapid effect taking, comfortable defecation and no stomachache and diarrhea. The normally physiological defecation of most patients with intractable constipation can be realized after the capsule is consecutively taken for nearly 1 month.
Description
One, technical field
The present invention relates to a kind of is the capsule and the production technology thereof of the treatment obstipation of primary raw material preparation with the Fructus Cucurbitae moschatae.
Two, background technology
The rhythm of current work, study, life is obviously accelerated, and social pressure increases, and causes the incidence rate of obstipation more and more higher, and health is threatened greatly.And the ubiquitous maximum drawback of product of state's internal therapy constipation has two to select at present: (1) raw material is many based on cathartic or even drastic purgative composition, takes medicine back stomachache and diarrhoea obviously.Because moisture is unbalance in the body, take for a long time in addition the enteric plexus nerve is caused damage, so in case drug withdrawal, constipation is but more serious, phenomenon appears relying on especially easily; (2) the material particles fineness of traditional handicraft processing only about the 100-140 order, absorbs slowly so enter in the body, and bioavailability is lower, so drug dose is big, medicining times is many, and clinical effectiveness is undesirable.
Employing as primary raw material, is resolved safely the method for constipation with Fructus Cucurbitae moschatae, yet there are no report.
Three, summary of the invention
The present invention is intended to overcome the above-mentioned disadvantage and the shortcoming of relieving constipation preparation in the past, proposes a kind of new capsule formula and production method thereof.Viewpoint according to motherland's medical science " equilibrium between yin and yang ", both considered clearing away heat-fire and YIN nourishing invigorating middle warmer complementary relationship, again in conjunction with scientific and reasonable adjustment prescriptions of characteristics such as the whole intestinal theories of modern medicine intestinal microecology, adopt advanced air-flow ultra-fine grinding technology simultaneously, the fineness of the particles of main and auxiliary material is not being damaged under the bioactive prerequisite, reached more than 500 orders.The capsule that has guaranteed preparation enters disintegrate absorption rapidly in the body, and bioavailability is stable to be improved.And little based on safety, no pain, consumption, take that number of times is few, instant effect, nothing rely on, do not rebound etc., reaches the purpose of the therapeutic effect that significantly improves obstipation.
Technology contents of the present invention is: the capsule that with the Fructus Cucurbitae moschatae is the treatment constipation of primary raw material preparation, seven flavor raw materials according to following weight proportion are formed Fructus Cucurbitae moschatae clothing 20-40%, Pedicellus Cucurbitae 10-30%, Fructus Cucurbitae moschatae network 5-15%, Poria 5-10%, Tremella 5-12%, Aloe 8-12%, oligomeric xylose 10-20%.
With the Fructus Cucurbitae moschatae is the capsular preparation method of the treatment constipation of primary raw material preparation, and step is as follows:
(1) chooses by weight ratio that Fructus Cucurbitae moschatae clothing, Pedicellus Cucurbitae, Fructus Cucurbitae moschatae network, Poria, 5 kinds of raw materials of Tremella are selected, after the roguing, soaks;
(2) decoct 3 times;
(3) collecting decoction, filtration;
(4) simmer down to thick paste;
(5) choosing Aloe by weight ratio pulverizes, sieves;
(6) with concentrated thick paste and Aloe fine powder mix homogeneously such as above-mentioned Fructus Cucurbitae moschatae clothing;
(7) cold drying;
(8) with the airflow milling ultra-fine grinding of above-mentioned material;
(9) above-mentioned micropowder fully is mixed into final material with oligomeric xylose;
(10) branch is encapsulated.
The present invention since in the side by the function of the gentleness detoxifcation of Fructus Cucurbitae moschatae, relieving constipation and " walking crosswise meridians ", play safety and gentle basic defecating feces excretion; By the effect of aloetic heat clearing away diarrhea inducing, strengthen the relieving constipation effect simultaneously; And the YIN nourishing of promoting the production of body fluid of Tremella, the spleen invigorating invigorating middle warmer function of Poria, then can further play stable large intestine moisture, the promotion relieving constipation effect of keeping on the one hand, on the other hand, can also prevent to a certain extent that Aloe is in the clearing away heat and loosing the bowels process, the body fluid that may cause is unbalance, after avoiding causing realizing normal relieving constipation, occurs " bounce-back " phenomenon again and takes place; In addition, utilize oligomeric xylose can strengthen the propagation of bacillus bifidus in the intestinal, reduce the intestinal pH value, environment in improving, thus remove metabolite, increase stool moisture, further promote enterokinesia, guarantee the stable intestinal motive force of safeguarding lastingly.All medicines share, and promote mutually, condition each other, and are collaborative with aforementioned all medicines, receive the effect of comparatively equilibrated safe loosening bowel to relieve constipation altogether.Diseases such as therefore, the present invention's capsule is applicable to cureless obstipation, and, constipation smooth to long-term bitter taste in the mouth and dry throat, anorexia, abdominal part overflow, aerofluxus, feces volume are few and difficult have remarkable, safe curative effect.
The capsule of process that employing the present invention relates to preparation, adjuvants such as major ingredient such as Fructus Cucurbitae moschatae clothing, Pedicellus Cucurbitae, Fructus Cucurbitae moschatae network and Poria, Tremella, Aloe have obtained superfine grinding, reach more than 500 orders.The fineness of the particles of main and auxiliary material is not being damaged under the bioactive prerequisite, obtained sufficient mixing, divide encapsulated with the superfine mixed powder.
Sample capsules with the preparation of the method that the present invention relates to is not limited by age, sex, physiological condition, is suitable for the obstipation that a variety of causes causes (comprise old, puerpera, child, operation after patient etc.) crowd and takes; Particularly can also prevent the usefulness of the special project health care that cordis and cerebral accident takes place as the patient that obstipation suffers from serious hypertension, cardiovascular and cerebrovascular disease simultaneously; In addition, product of the present invention also has good result to removing enterotoxin and blood toxicity and skin care.And consumption is little, take number of times few (every day only 1 time is about average 0.4 gram), instant effect (rapid constipation relieving of the same day or next day), and it is very light that defecation is felt, do not have stomachache and diarrhoea.The patient of most obstipations takes about 1 month continuously, just can realize the normal physiological defecation.
For showing safety of the present invention and to the therapeutic effect of obstipation, the following test that the present invention has finished:
(1) safety toxicological evaluation.
Testing result: belong to actual nontoxic level material; Salmonella reversion test, mouse bone marrow cells micronucleus test and the test of mouse sperm distortion analysis detect negative; 30 days feeding trials do not see that it has any toxicity damage effect to animal subject.
Test item:
1. acute toxicity test (detailed process slightly)
2. genetic toxicity test (detailed process slightly)
3. 30 days feeding trials (detailed process slightly)
Detect conclusion:
1. acute toxicity test: test with the large and small Mus per os acute toxicity (LD of sample to two kinds of sexes
50) all greater than 10.00g/kgBW, according to the acute toxicity classification, true border is nontoxic.
2. genetic toxicity test: the result shows the hereditary-less toxicity effect.
(1) Salmonella reversion test: the result is negative.
(2) PCEMNR micronucleus test: the result is negative.
(3) mouse sperm deformity test: the result is negative.
3. 30 days feeding trials of rat: experimental group that Clinical Laboratory, blood biochemical are learned and checked, the internal organs weighing result shows each inspection item and matched group comparison, difference is not remarkable.The result of histopathologic examination shows that liver,spleen,kidney, stomach, intestinal, the testis (ovary) of matched group and high dose group hero, female rats there is no the histopathology relevant with empirical factor and change.
(2) bowel relaxing functions animal experiment.
Testing result: according to " health food check and technical specification " (2003 editions) criterion that health ministry is worked out, the present invention has good bowel relaxing functions, and animal is had no adverse effects.
Detection method:
1. intestinal motility experiment
2. the mensuration of mice defecation time, fecal grains and stool weight
Detect content:
1. sample is to the influence of mice body weight
2. sample is to the influence of prepared Chinese ink propelling rate
3. sample is to the influence of defecation time
4. sample is to the influence of defecation grain number
5. sample is to the influence of defecation weight
Check conclusion:
Per os gives the sample 12 days of mice various dose, and between model control group (0g/kgBW) relatively, 0.1g/kgBW organizes every index does not all have significant difference P＞0.05; 0.2g/kg organizing every index, BW all do not have significant difference P＞0.05; 0.6g/kg the BW group can shorten mice defecation time P＜0.05, increases mice row melena grain and counts P＜0.01, increases mice defecation weight P＜0.05, weight of mice has no adverse effects.According to " health food check with assessment technique standard) " (2003 editions) to the criterion of bowel relaxing functions health food as can be known, sample has bowel relaxing functions.
(3) clinical bowel relaxing functions viewing test.
Test item: bowel relaxing functions human feeding trial
Test basis: " the health food function assessment assessment process and the method for inspection "
Result and judgement: 100 satisfactory constipation experimenters, the test-meal group is taken sample capsules, and 3 every night, every day 1 time, matched group is taken positive reference substance old man constipation-relieving tea, and each 2 bags, are and take 15 days continuously every day 1 time.The defecation frequency of test-meal group as a result obviously increases by 2.92 ± 2.26 times, feces character deliquescing 1.20 ± 0.67 degree, defecation condition is improved 1.26 ± 0.80 grades, the matched group defecation frequency obviously increases by 2.34 ± 1.59 times, feces character deliquescing 1.18 ± 0.75 degree, and defecation condition is improved 1.10 ± 0.71 grades, routine blood test, routine urinalysis and blood biochemistry index are all in normal range before and after two groups of test-meals, can think that sample has bowel relaxing functions, and the healthy nothing of examination trencherman is obviously influenced.
1. object and method
1.1 tried thing: sample capsules is provided by the inventor.Positive reference substance: old man's constipation-relieving tea, Nanning city five power HANYAO institutes are produced.Lot number: No. the 558th, hygienic food and health number (1998).Date of manufacture: 20020202.
1.2 study subject: press the principle of voluntariness and select 18-65 year, constipation experimenter 100 examples.
1.2.1 diagnostic criteria: infrequent defecation time lengthening, the big dry and hard or involved and abstruse not smooth functional constipation person of potbellied matter.
1.2.2 the person's of including in standard:
1.2.2.1 defecation frequency reduces and feces hardness enhancer.
Be less than 3 times the person week 1.2.2.2 defecate.
1.2.2.3 there is not organic constipation person.
1.2.2.4 habitual constipation person.
1.2.3 eliminator's standard:
1.2.3.1 the age, gestation or women breast-feeding their children were to these health product allergy sufferers under-18s or over-65s person.
1.2.3.2 be associated with serious primary disease such as conscience kidney and hemopoietic system, or other accompanying diseases arranged just in therapist, the psychotic.
1.2.3.3 do not meet the standard of including in, do not take in accordance with regulations and tried thing, there are not the effect of judgement or data not umbra sound effect or safety judgement person.
1.3 contrast form: adopt two kinds of EXPERIMENTAL DESIGN of contrast between self and group; Positive controls is taken old man's constipation-relieving tea of defecating feces excretion.
1.4 taking dose and time: the test-meal group is taken 3 of capsules every night, and every day 1 time, matched group is taken old man's constipation-relieving tea, and each 2 bags, every day 1 time, continuous 15 days, the experimenter cut out medicine or other health product of relevant loosening bowel to relieve constipation at experimental session.
1.5 instrument and reagent: ten analysers of MEK-6318K type blood counting instrument (Japan produces) NIDIRON urine (Germany produces), automatic clinical chemistry analyzer (U.S.'s product) model RA1000, the biochemical reagents box is all provided by middle living company.
2. observation index:
Each is checked once before and after the experiment.
2.1 ordinary circumstance: detailed medical history-taking, understand experimenter's spirit, sleep, diet, observation main clinic symptoms: feeling of fullness, abdominal distention, dry stool knot, involved and abstruse not smooth situation.By the mild symptoms multiple integral, calculate the doing well,improving rate.
2.2 effect observation:
2.2.1 every day defecation frequency:
2.2.2 defecation condition: be divided into the I-IV level according to difficult defecation, the statistics integrated value.
I level (0 minute): defecation is normal.
II level (1 minute): bearing down, sense of discomfort are only arranged.
III level (2 minutes): bearing down, sense of discomfort are obvious, or have just frequently but difficult defecation and measure few, less appearance stomachache or anus burn feeling.
IV level (3 minutes): stomachache or anus burn feeling often occur, influence defecation.
2.2.3 feces character: the feces character is divided into I-III level according to Bristol feces character classification method.
I level (0 minute):, level and smooth and soft as sausage or Serpentis; The picture sausage, but slight crack is arranged on its surface; Soft agglomerate has tangible edge (easily discharging).
II level (1 minute): the sausage character, but agglomerate is arranged: the bulk of pine, edge roughness is as slimy feces.
III level (2 minutes): isolating hard group, as pit (being difficult for discharging).
2.3 safety is observed:
2.3.1 blood and hematuria routine examination:
Red blood cell count(RBC), hemoglobin, numeration of leukocyte is urinated ten detections.
2.3.2 biochemical indicator is measured:
Serum albumin ALB, total protein TP, darling renal function (glutamic oxaloacetic transaminase, GOT AST, glutamate pyruvate transaminase ALT, uremic UREA, inosine CRE), blood glucose GLu, blood fat (T-CHOL TC, triglyceride TG).
2.3.3 Abdominal B type ultrasonography, electrocardiogram, the fluoroscopy of chest of x line.
3. the defecation effect is judged:
Effectively: defecation frequency obviously increases, and an index integration obviously descends in the defecation condition feces character binomial index, and difference has significance.
Invalid: defecation frequency does not have obvious increase, and defecation condition and feces character do not have significant change.
4. experimental result:
4.1 general situation:
Observe constipation experimenter 100 examples altogether, be divided into two groups at random.
4.2 situation was relatively as two groups of observations were last:
Situation comparison as table l observation is last (X ± SD)
| Grouping | Example number (example) | Age (year) | The man | The woman | The course of disease (year) | Constipation (inferior/week) |
| The examination trencherman | 50 | 42.12±10.68 | 15 | 35 | 6.54±4.75 | 2.30±0.65 |
| Matched group | 50 | 45.46±8.34 | 25 | 25 | 5.59±4.82 | 2.58±0.54 |
Two groups have P between the comparability group＞0.05
4.3 defecation frequency changes:
Table 2 defecation frequency changes (inferior/week)
| The example number | Before the test-meal | After the test-meal | Difference |
| The examination trencherman | 50 | 2.30±0.65 | 5.22±2.46 | 2.92±2.26 |
| Matched group | 50 | 2.58±0.54 | 4.92±1.78 | 2.34±1.59 |
*#P＞0.05 between P＜0.01 group
4.4 defecation condition changes:
Table 3 integral of defecation condition changes (level)
| The example number | Before the test-meal | After the test-meal | Difference | |
| The examination trencherman | 50 | 2.02±0.59 | 0.76±0.77 | -1.26±0.80 ** |
| Matched group | 50 | 1.96±0.49 | 0.86±0.70 | -1.10±0.71 ** |
*#P＞0.05 between P＜0.0l group
4.5 the feces character changes:
Table 4 feces character integration changes (degree)
| The example number | Before the test-meal | After the test-meal | Difference | |
| The examination trencherman | 50 | 1.82±0.39 | 0.62±0.60 | -1.20±0.67 ** |
| Matched group | 50 | 1.94±0.24 | 0.76±0.74 | -1.18±0.75 ** |
*#P＞0.05 between P＜0.01 group
4.6 the variation of clinical symptoms before and after the test-meal:
The variation of clinical symptoms before and after table 5 test-meal
| Symptom | Produce effects (example) | Effectively (example) | Invalid (example) | Improvement rate % | ||||
| Matched group | Observation group | Matched group | Observation group | Matched group | Observation group | Matched group | Observation group | |
| Feeling of fullness | 4 | 8 | 26 | 25 | 3 | 10 | 81.82 | 76.74 |
| The dry stool knot | 12 | 16 | 22 | 25 | 8 | 8 | 80.95 | 83.67 |
| Involved and abstruse not smooth | 18 | 20 | 22 | 22 | 10 | 7 | 80.00 | 80.56 |
4.7 symptom integral changes:
Table 6 symptom integral changes
| The example number | Before the test-meal | After the test-meal | Difference | |
| The examination trencherman | 50 | 13.00±6.15 | 5.86±4.89 | 7.14±4.15 ** |
| Matched group | 50 | 12.86±3.98 | 6.00±2.57 | -6.86±3.87 ** |
*#P＞0.05 between P＜0.0l group
4.8 safety indexes detects: (detailed process slightly)
4.9 Abdominal B type ultrasonography, electrocardiogram, the fluoroscopy of chest of X line is all in normal range
5. conclusion:
5.1 100 routine constipation experimenters took sample capsules and old man's constipation-relieving tea 15 days on request, test-meal group as a result defecation frequency weekly increases by 2.92 ± 2.26 times, feces character deliquescing 1.20 ± 0.67 degree, defecation condition is improved 1.26 ± 0.80 grades, matched group defecation frequency weekly increases by 2.34 ± 1.59 times, feces character deliquescing 1.18 ± 0.75 degree, defecation condition is improved 1.10 ± 0.71 grades, and interpret sample capsule and old man's constipation-relieving tea all have bowel relaxing functions.
5.2 sample capsules has the improvement effect to feeling of fullness, dry stool, involved and abstruse symptom such as not smooth.
5.3 before and after the sample capsules test-meal, hemoglobin, erythrocyte, leukocyte, total serum protein, albumin, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, inosine, carbamide, blood glucose, blood fat and routine urinalysis etc. detect index all in normal range, illustrate that this product has no adverse effects to the experimenter is healthy.
5.4 after the sample capsules test-meal, do not meet quick and other untoward reaction.
Four, the specific embodiment
The present invention will further be illustrated by following examples.
With the Fructus Cucurbitae moschatae is the capsule formula of the treatment constipation of primary raw material preparation, and the weight proportion of each raw material is: Fructus Cucurbitae moschatae clothing 30%, Pedicellus Cucurbitae 18.5%, Fructus Cucurbitae moschatae network 11.5%, Poria 7%, Tremella 8%, Aloe 11%, oligomeric xylose 14%.
With the Fructus Cucurbitae moschatae is the capsular preparation method of the treatment constipation of primary raw material preparation, and step is as follows:
(1) chooses by weight ratio that Fructus Cucurbitae moschatae clothing, Pedicellus Cucurbitae, Fructus Cucurbitae moschatae network, Poria, 5 kinds of raw materials of Tremella are selected, after the roguing, soaks;
(2) decoct 3 times;
(3) collecting decoction, filtration;
(4) simmer down to thick paste;
(5) choosing Aloe by weight ratio pulverizes, sieves;
(6) with concentrated thick paste and Aloe powder mix homogeneously such as above-mentioned Fructus Cucurbitae moschatae clothing;
(7) cold drying;
(8) with the airflow milling ultra-fine grinding of above-mentioned material;
(9) above-mentioned micropowder fully is mixed into final material with oligomeric xylose;
(10) branch is encapsulated.
According to a kind of be the capsular preparation method of primary raw material preparation treatment obstipation with the Fructus Cucurbitae moschatae, described step (1) is removed impurity, that step (2-6) is extracted, boiled is concentrated, add the Aloe powder premix, and step (7) cold drying makes moisture≤8%, ash≤5% in the raw material.
According to a kind of be the capsular preparation method of primary raw material preparation treatment obstipation with the Fructus Cucurbitae moschatae, described step (8-9) ultra-fine grinding is handled, and is to be 500 orders with extract such as Fructus Cucurbitae moschatae clothing, Pedicellus Cucurbitae, Fructus Cucurbitae moschatae network, Poria, Tremella and final pulverizing of Aloe; Oligomeric xylose is original powdery.
Claims (4)
1. one kind is the capsule of the treatment obstipation of primary raw material preparation with the Fructus Cucurbitae moschatae, it is characterized in that making Fructus Cucurbitae moschatae clothing 20-40%, Pedicellus Cucurbitae 10-30%, Fructus Cucurbitae moschatae network 5-15%, Poria 5-10%, Tremella 5-12%, Aloe 8-12%, oligomeric xylose 10-20% according to seven flavor raw materials of following weight proportion.
According to claim 1 described a kind of be the capsule of the treatment obstipation of primary raw material preparation with the Fructus Cucurbitae moschatae, it is characterized in that the weight proportion of described each raw material is: Fructus Cucurbitae moschatae clothing 30%, Pedicellus Cucurbitae 18.5%, Fructus Cucurbitae moschatae network 11.5%, Poria 7%, Tremella 8%, Aloe 11%, oligomeric xylose 14%.
Claim 1 described a kind of be the capsular preparation method of the treatment obstipation of primary raw material preparation with the Fructus Cucurbitae moschatae, it is characterized in that may further comprise the steps:
(1) chooses by weight ratio that Fructus Cucurbitae moschatae clothing, Pedicellus Cucurbitae, Fructus Cucurbitae moschatae network, Poria, 5 kinds of raw materials of Tremella are selected, after the roguing, soaks;
(2) decoct 3 times;
(3) collecting decoction, filtration;
(4) simmer down to thick paste;
(5) choosing Aloe by weight ratio pulverizes, sieves;
(6) with concentrated thick paste and Aloe fine powder mix homogeneously such as above-mentioned Fructus Cucurbitae moschatae clothing;
(7) cold drying;
(8) with the airflow milling ultra-fine grinding of above-mentioned material;
(9) above-mentioned micropowder fully is mixed into final material with oligomeric xylose;
(10) branch is encapsulated.
According to claim 3 described a kind of be the capsular preparation method of the treatment obstipation of primary raw material preparation with the Fructus Cucurbitae moschatae, it is characterized in that described step (7) cold drying, make moisture≤8%, ash≤5% in the raw material; Step (8) ultra-fine grinding is handled, and is to be 500 orders with extract such as Fructus Cucurbitae moschatae clothing, Pedicellus Cucurbitae, Fructus Cucurbitae moschatae network, Poria, Tremella and final pulverizing of Aloe; Oligomeric xylose is original powdery.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410013663 CN1231255C (en) | 2004-04-07 | 2004-04-07 | Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410013663 CN1231255C (en) | 2004-04-07 | 2004-04-07 | Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1533805A CN1533805A (en) | 2004-10-06 |
| CN1231255C true CN1231255C (en) | 2005-12-14 |
Family
ID=34305413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410013663 Expired - Lifetime CN1231255C (en) | 2004-04-07 | 2004-04-07 | Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1231255C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412204B (en) * | 2015-12-03 | 2020-06-26 | 青岛市中心医院 | Pharmaceutical composition for treating senile constipation and application thereof |
| CN111202797A (en) * | 2019-11-14 | 2020-05-29 | 河北御芝林药业有限公司 | New application of laxative formula with five fruits and vegetables as raw materials for increasing gastrointestinal motility and promoting gastrointestinal emptying |
| CN111202796A (en) * | 2019-11-14 | 2020-05-29 | 河北御芝林药业有限公司 | New application of cathartic composition prepared from five fruits and vegetables in enhancing gastrointestinal motility and promoting digestion |
| CN111202789A (en) * | 2019-11-14 | 2020-05-29 | 河北御芝林药业有限公司 | New application of bowel relaxing formula with five fruits and vegetables as raw materials for increasing intestinal moisture and lubricating intestinal tract |
| CN111202798A (en) * | 2019-11-14 | 2020-05-29 | 河北御芝林药业有限公司 | New application of bowel relaxing formula with five fruits and vegetables as raw materials for increasing intestinal mucus layer and protecting intestinal tract |
| CN111202800A (en) * | 2020-03-09 | 2020-05-29 | 河北御芝林药业有限公司 | New application of bowel relaxing formula with five fruits and vegetables as raw materials for enhancing immunity |
-
2004
- 2004-04-07 CN CN 200410013663 patent/CN1231255C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1533805A (en) | 2004-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1887101A (en) | Slimming tea and its prepn | |
| CN1939477A (en) | Chinese-medicinal composition for treating enterogastric diseases | |
| CN1957724A (en) | Tea for lowering fat and reducing weight, and preparation method | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN101057643A (en) | Rice with blood sugar reducing function | |
| CN1813868A (en) | Composition for treating and improving chronic fatigue syndrome and its preparing method | |
| CN1231255C (en) | Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method | |
| CN1883527A (en) | A health product of lucid ganoderma and preparation method thereof | |
| CN1253159C (en) | Health product of compound propolis and preparing method | |
| CN1493208A (en) | Dietary fiber powder pouring boiling water for eating | |
| CN1169259A (en) | Nutritious powder for strengthening bone and tonifying brain, and preparation method | |
| CN1176602C (en) | Health food capable of increasing bone density and delaying senility and its production process | |
| CN102018212B (en) | Red yeast rice capsules and preparation method thereof | |
| CN1857350A (en) | Immunological function strengthening medicine and health product and their preparing method | |
| CN1682910A (en) | Chinese patent medicine on health food composition and its use | |
| CN1309318C (en) | Body building nutrient | |
| CN105995980A (en) | Composition with weight management function and preparation method thereof | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1257736C (en) | Sobering-up liver-protecting medicine composition for preventing chemical liver damage and its prepn process | |
| CN1857632A (en) | Osteoporosis treating compound Chinese preparation and its preparing process | |
| CN1565554A (en) | Fat reducing Chinese drugs for treating simple obesity | |
| CN1723801A (en) | Health-care food with functions of relaxing the bowels and beautifying, and its prepn. method | |
| CN1386511A (en) | Medicine for preventing and treating senile dementia | |
| CN1593493A (en) | Therapy assisting agent and its preparation | |
| CN1613482A (en) | Composition for improving memory and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEBEI YUZHILIN PHARMACEUTICAL CO., LTD. Effective date: 20120504 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 150040 HARBIN, HEILONGJIANG PROVINCE TO: 054400 XINGTAI, HEBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120504 Address after: 054400 five kilometers east exit of Xingtai City, Hebei Province Patentee after: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Address before: 150040 No. 216, Wenchang street, Power District, Heilongjiang, Harbin Co-patentee before: Yu Chunlin Patentee before: Jin Jianwen |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method Effective date of registration: 20150827 Granted publication date: 20051214 Pledgee: Shijiazhuang Bao small and medium-sized enterprise guarantee service Co.,Ltd. Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: 2015990000728 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20161118 Granted publication date: 20051214 Pledgee: Shijiazhuang Bao small and medium-sized enterprise guarantee service Co.,Ltd. Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: 2015990000728 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method Effective date of registration: 20161118 Granted publication date: 20051214 Pledgee: Shijiazhuang Bao small and medium-sized enterprise guarantee service Co.,Ltd. Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: 2016990000998 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| CP02 | Change in the address of a patent holder |
Address after: 054400 Hebei province Xingtai city east exit five kilometers (South and County Industrial Park) Patentee after: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Address before: 054400 five kilometers east exit of Xingtai City, Hebei Province Patentee before: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180404 Granted publication date: 20051214 Pledgee: Shijiazhuang Bao small and medium-sized enterprise guarantee service Co.,Ltd. Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: 2016990000998 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method Effective date of registration: 20180423 Granted publication date: 20051214 Pledgee: Bank of China Limited by Share Ltd. Shijiazhuang Yuhua branch Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: 2018130000005 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20181010 Granted publication date: 20051214 Pledgee: Bank of China Limited by Share Ltd. Shijiazhuang Yuhua branch Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: 2018130000005 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181102 Address after: 050000 Haihe Road 168, hi tech Zone, Shijiazhuang, Hebei Patentee after: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Address before: 054400 five kilometers east exit of Xingtai City, Hebei province (South County Industrial Park) Patentee before: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method Effective date of registration: 20190404 Granted publication date: 20051214 Pledgee: Bank of China Limited by Share Ltd. Shijiazhuang Yuhua branch Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: 2019130000003 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200430 Granted publication date: 20051214 Pledgee: Bank of China Limited by Share Ltd. Shijiazhuang Yuhua branch Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: 2019130000003 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method Effective date of registration: 20200511 Granted publication date: 20051214 Pledgee: Bank of China Limited Hebei Branch No.2 business department Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020130000011 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210603 Granted publication date: 20051214 Pledgee: Bank of China Limited Hebei Branch No.2 business department Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020130000011 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The capsule formula and preparation method of treating constipation with pumpkin as main raw material Effective date of registration: 20210603 Granted publication date: 20051214 Pledgee: Bank of China Limited Shijiazhuang Branch Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021130000012 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220624 Granted publication date: 20051214 Pledgee: Bank of China Limited Shijiazhuang Branch Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021130000012 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Capsule formula and preparation method for treating constipation prepared with pumpkin as the main raw material Effective date of registration: 20220628 Granted publication date: 20051214 Pledgee: Bank of China Limited Shijiazhuang Branch Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: Y2022130000041 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230823 Granted publication date: 20051214 Pledgee: Bank of China Limited Shijiazhuang Branch Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: Y2022130000041 |
|
| CX01 | Expiry of patent term |
Granted publication date: 20051214 |
|
| CX01 | Expiry of patent term |